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Abstract
Sclareol is an organic compound with potential anti-tumor effects against various cancer types. 
However, its precise molecular mechanism in the suppression of tumor growth has not been fully 
elucidated. In the present study, the anti-proliferative and apoptosis-inducing effects of sclareol 
with cyclophosphamide were investigated in breast cancer cells and the involvement of the JAK/
STAT pathway was evaluated. For this purpose, MCF-7 breast cancer cells were cultured and 
treated with various concentrations of sclareol to determine its IC50. Cell viability was measured 
by MTT assay and apoptosis was assessed by flow cytometric analysis of annexin V binding. 
Gene and protein expression were examined by real-time PCR and Western blotting, respectively. 
The activity of caspase enzymes was also measured. The results showed that sclareol significantly 
reduced cell viability and triggered cell death and its co-administration with cyclophosphamide 
enhanced its anti-cancer properties. Additionally, sclareol up-regulated the expression of 
p53 and BAX and reduced the expression of Bcl-2. Docking studies indicated an interaction 
between sclareol and STAT3 which was proved by attenuation of STAT3 phosphorylation after 
treatment of the cells with sclareol. Sclareol was also capable of suppressing the function of 
IL-6 in modulating the expression of apoptosis-associated genes. Altogether these data suggest 
the potential of sclareol as an anti-cancer agent and demonstrate that a combination of sclareol 
with cyclophosphamide might serve as an effective chemotherapeutic approach resulting in 
improvements in the treatment of breast cancer. 
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Introduction
Breast cancer was the most frequently 
diagnosed cancer among women worldwide and 
the leading cause of cancer mortality for women 
ages 20 and 59 years in the United State in 2018. 
About 41,000 American female patients were 
expected to die from breast cancer in 2018 
(1, 2). Recent epidemiological data indicate 
that 1 in 8 women will be diagnosed with 
breast cancer during her life and its long-term 
incidence rates are slightly increased by 0.4% 
per year (3). According to a study, the highest 
incidence rates of breast cancer were reported in 
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North America and western Europe. However, 
the global incidence trend of this cancer is rising 
particularly in countries with a low incidence 
rate like Iran (4). Treatment options for breast 
cancer therapy include endocrine therapy for 
hormone receptor-positive tumors, antibody-
based medications, and chemotherapy (5). The 
same basic categories of systemic therapy are 
used in metastatic breast cancer; nevertheless, 
metastatic breast cancer remains incurable in 
virtually all affected patients and therefore 
new modalities and medication regimens are 
needed for the management of breast cancer 
(5). Recently, there has been a tendency to 
replace old drug therapy regimens with the 
newer combination therapy methods (6, 7). In 
this way, a wide variety of studies have shown 
that some drugs such as cyclophosphamide 
can be effective for breast cancer management 
especially when combined with other anti-
cancer agents (8). For example, the docetaxel-
cyclophosphamide combination is an efficient 
and conventionally used chemotherapy strategy 
in the adjuvant and neoadjuvant regimen for the 
patients with breast cancer in its early stages (9). 
Cyclophosphamide is one of the most widely 
utilized alkylating agents with cytotoxic and 
immunosuppressive activities typically used 
in combination with other medications for the 
treatment of breast cancer (10-12). Moreover, 
cyclophosphamide was reported to partially 
exert its anti-tumoral activity by blocking the 
p-STAT3 pathway (13). 
Sclareol (Labd-14-ene-8, 13-diol) is a 
labdane diterpene, extracted from Salvia 
sclarea, with anti-cancer properties against 
various types of cancers (14-16). In breast 
cancer, sclareol has been shown capable of 
inhibiting DNA synthesis, inducing cell cycle 
arrest and triggering apoptosis. Additionally, 
sclareol has been introduced as a potent 
enhancer for the activity of well-known 
chemotherapy agents such as doxorubicin, 
etoposide, and cisplatin, against breast cancer 
cells (16). 
Derangement of cytokines is a common 
finding in breast cancer. Elevation of IL-6 in the 
tumor microenvironment has been demonstrated 
in various types of cancers such as breast 
cancer. IL-6 is able to modify many aspects 
of tumorigenesis by affecting proliferation, 
cellular metabolism, survival, apoptosis, 
angiogenesis, and metastasis through activation 
of the JAK/STAT3 pathway (17). We had 
previously shown the effectiveness of sclareol 
in reducing the tumor volume, suppressing the 
regulatory T cells and shifting the cytokine 
profile with decreasing interleukin-4 (IL-4) and 
augmenting IFN-γ (18). 
In this study, we aimed to investigate 
the effect of sclareol on cell viability and 
apoptosis either alone or combined with 
cyclophosphamide. We also evaluated the 
effectiveness of sclareol to modulate IL-6-
mediated alterations in apoptosis through 
inhibition of STAT3.
Experimental
 Molecular docking studies
To determine whether sclareol is able to 
directly bind to the SH2 domain of STAT3, 
the pharmacophore model was built based on 
the three-dimensional structure of the STAT3β 
homodimer-DNA complex (PDB: 1BG1) 
(19). For the generation of the pharmacophore 
model, the sequence corresponding to residues 
M586-F716 of STAT3β, comprising its SH2 
domain, was taken into account as the receptor. 
The receptor-based pharmacophore model 
was created with the software Autodock Vina.
 
Cell culture and treatment
The normal breast cell line, MCF-10A, 
and the human breast cancer cell line MCF-
7, were purchased from Cell Bank of Pasteur 
Institute (Tehran, Iran). All cell lines were 
grown in RPMI 1640 medium supplemented 
with 10% fetal bovine serum (FBS) and 
penicillin (100 U/ml)/streptomycin (100 μg/
mL). All cell lines were then incubated in a 
humidified incubator with 5% CO2 for 24 h 
or 48 h at 37 °C. The materials for cell culture 
were obtained from Gibco, UK. Sclareol, 
and cyclophosphamide were purchased from 
Sigma-Aldrich (Germany). For cell treatment, 
sclareol was dissolved in ethanol and sclareol-
free ethanol served as the negative control.
Cell viability
Cell viability was determined using 
the Vybrant MTT cell proliferation assay 
kit (Thermo Fischer Scientific, USA) 
containing 3-(4,5-Dimethylthiazol-2-yl)-2,5-
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diphenyltetrazolium bromide (MTT), as a 
water-soluble tetrazolium salt, according to 
the manufacturer’s protocol. Exponentially 
growing MCF-7 cells were seeded at a density 
of 2×104 cells/well into 96-well tissue culture 
plates with a total volume of 200 µl per well. 
Different concentrations of sclareol (10-150 
µM) and cyclophosphamide (5-40 μM) were 
added. For evaluating the combination of 
sclareol and cyclophosphamide on cell viability, 
8 μM concentration of cyclophosphamide 
together with 10-40 μM concentrations of 
sclareol were employed. Thereafter, the cells 
were incubated for 24 and 48 h at 37°C. The 
quantity of the formed soluble formazan 
was calculated through the measurement of 
absorbance at 490 nm using a plate reading 
spectrophotometer (PerkinElmer, USA).
Real-time PCR
Full-length sequences of the genes of interest 
including STAT3, JAK2, B cell lymphoma 2 
(Bcl-2), Bcl-2 associated X protein (BAX), 
and p53 were retrieved from NCBI database 
and recruited for primer design by Primer 
Express software v1.5 (Applied Biosystems). 
The primer sequences are presented in 
Table 1. Total RNA was extracted from the 
cells using the RNeasy mini kit (Qiagen, 
Germany), according to the manufacturer’s 
protocol. M-MLV reverse transcriptase, 
encoded by Moloney murine leukemia virus 
(M-MLV RT, Gibco) and oligo-d(T)15 primer 
(Roche Applied Sciences, Germany) were used 
to synthesize complementary DNA (cDNA) 
strand from the 1 µg/ml solution of single-
stranded RNA. Real-time PCR analyses were 
performed on cDNA samples by SYBR-green 
master mix (Ampliqon, Denmark) using ABI 
PRISM 7900HT (Applied Biosystems, USA) 
under the thermocycling conditions as follows: 
an individual heating phase at 95 °C for 15 
minutes, followed by 40 cycles of 95 °C for 15 
seconds (denaturation phase) and 60 °C for 30 
seconds (annealing phase/extension phase). 
Melt curve analysis was also performed for 
each gene to verify the specificity of primers 
and the lack of non-specific products. The final 
results were analyzed by the 2-ΔΔCt method 
with GAPDH as the normalizer. 
Flow Cytometry
The effect of sclareol on apoptosis 
was investigated using a FITC/annexin-
V-propidium iodide (PI) kit (apoptosis 
detection kit; R&D Systems) following 
the manufacturer’s protocol. MCF-
7 cells were treated with sclareol (30 
µM), cyclophosphamide (8 μM) or their 
combination. Subsequently, the treated cells 
Table 1. Primer sequences 
 















R: 5'- TCATCCAAATACTCCACACGC-3' 
 
Table 1. Primer sequences
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were centrifuged (1000 g) for 5 min at room 
temperature (18-24 °C), washed once with 
5 mL phosphate-buffered saline (PBS) and 
then resuspended in binding buffer. Five 
microliters of FITC-annexin V and 5 µL of 
PI were added to the cell suspension and 
incubated for 10 min in the dark at room 
temperature. Analysis of FITC-Annexin V 
binding was carried out on a FAC scan flow 
cytometer (BD Biosciences) with an emission 
wavelength of 350 nm and an excitation 
wavelength of 488 nm. The tests were 
performed in three independent experiments. 
Annexin V positive /PI negative cells were 
reported as early apoptotic cells while those 
positively stained by both Annexin V and 
PI were considered as late apoptotic cells. 
Annexin V negative/ PI-positive cells were 
presented as necrotic cells. 
Western blot analysis
MCF-7 cells were seeded in six-well 
culture plates and allowed to adhere to the 
plate overnight. Subsequently, they were 
then incubated with the sclareol solution (30 
μM). A group of cells was additionally treated 
with IL-6 (50 ng/mL) 4 hours after treatment 
with sclareol. The cells were harvested by 
centrifugation at 412 g for 10 min, washed 
twice with PBS and suspended in RIPA lysis 
buffer (Thomas Scientific Inc., USA) for 
preparation of whole-cell lysates. The lysates 
were centrifuged and the supernatant was used 
for Western blot analysis. Bicinchoninic acid 
(BCA) assay kit (Thermo Fisher Scientific, 
UK) was used to measure the protein content. 
The samples were subsequently loaded into 
10 % SDS-PAGE (40 µg total protein/lane) 
and transferred onto a polyvinylidene fluoride 
(PVDF) membrane (Millipore, USA) by 
electroblotting. The membranes were blocked 
with 5% non-fat milk at room temperature 
for 1 h. The membranes were then incubated 
overnight at 4°C with 1:1000 dilution of 
primary antibodies against STAT3 (Cell 
Signaling, Danvers, USA), phosphorylated 
STAT3 (Cell Signaling, Danvers, USA), 
and β-actin (Sigma-Aldrich, Germany). The 
membranes were incubated with corresponding 
horseradish peroxidase (HRP)-conjugated 
anti-mouse IgG (Santa Cruz Biotechnology, 
UK) for 1 h at room temperature, in the 
dark. Immunoblots were detected using an 
enhanced chemiluminescent kit (SuperSignal, 
Thermo Fisher Scientific, UK). The density 
of the visualized bands was quantitated using 
ImageJ software (NIH, Bethesda, USA).
Measurement of caspase activity
A colorimetric assay was used to determine 
caspase activity. For this purpose, MCF-
7  cells were lysed in lysis buffer (250 mM 
sucrose, 0.02 M Tris HCl pH 7.4, 1% Triton 
X-100, 150 mM NaCl, 1 mM EDTA, 1 mM 
EGTA, and 1 mM DTT) at 4 °C for 30 min 
while vortexing. A 200-μg sample of cell 
lysate protein was mixed in assay buffer 
(25 mM HEPES pH 7.5, 0.1% CHAPS, 5% 
sucrose, 5 mM DTT, and 2 mM EDTA) in a 
final volume of 100 μl, followed by addition 
of 10 μl of 2 mM of the substrate caspase-8 
(Z-IETD-pNA), caspase-9 (Ac-LEHD-pNA), 
or caspase-3 (Z-DEVDpNA) for the respective 
caspase assay. The reaction mixture was 
incubated at 37 °C for 30 min and liberated 
p-nitroaniline (pNA) was measured at 405 nm 
with a SpectraMAX 190 Microplate Reader 
(Sunnyvale, CA, USA).
Statistical Methods 
Data are expressed as the mean ± standard 
error of the mean. Statistical data analyses 
were carried out using one-way analysis of 
variance (ANOVA) followed by Duncan’s 
multiple range test for post-hoc evaluation. 
SPSS 17.0 software was used for the analysis 
of acquired data. For all analyses, P<0.05 was 
considered to indicate a statistically significant 
difference.
Results
Sclareol reduced cell viability and 
potentiated the cytotoxic activity of 
cyclophosphamide on breast cancer cells
The cytotoxic effect of sclareol on breast 
cancer cells was determined based on the 
levels of formazan formation in MTT assay. 
As shown in Figures 1A and B, sclareol 
caused a dose-dependent reduction of the 
survival of MCF-7 cells after 24 hours which 
became significant at the doses higher than 30 
μM. After 24 h of treatment, the IC50 value of 
sclareol was 31.11 μM and further decreased 
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to 27.65 μM after 48 h. The effect of 
cyclophosphamide on cell viability was also 
evaluated and it was shown that 24 h treatment 
of MCF-7 cells with cyclophosphamide caused 
a significant decline in the survival of MCF-7 
breast cancer cells at the dose of 3 μM with an 
IC50 value of 8.3 μM (Figure 1C). When the 
incubation time with cyclophosphamide was 
 
Figure 1- The effect of sclareol, after 24 h (A) and 48 h (B), cyclophosphamide after 24 h (C) and 48 h 
(D), or their combination after 24 h (E) and 48 h (F), on the viability of MCF-7 cells. Scl: sclareol; CPM: 
cyclophosphamide. The data shown are the mean ± SD of at least three separate experiments. The values 
were compared with the control. Treatment with IL-6 served as positive control. 
Figure 1- The effect of sclareol, after 24 h (A) and 48 h (B), cyclophosphamide after 24 h (C) and 48 h (D), or their combi-
nation after 24 h (E) and 48 h (F), on the viability of MCF-7 cells. Scl: sclareol; CPM: cyclophosphamide. The data shown 
are the mean ± SD of at least three separate experiments. The values were compared with the control. Treatment with IL-6 
served as positive control.
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extended for 48 h, the viability was further 
decreased and the IC50 value diminished to 7.6 
μM (Figure 1D). The lowest effective dose of 
cyclophosphamide in decreasing the viability 
was 0.5 μM after 48 hours of treatment.
In the next step cell viability was 
assessed in response to the combination 
of cyclophosphamide and sclareol. As it is 
presented in Figure 1E, co-administration of 
sclareol and cyclophosphamide resulted in a 
more remarkable reduction in cell survival 
compared to cyclophosphamide alone in 
MCF-7 cells. Increasing the dose of sclareol 
combined with 8 μM cyclophosphamide 
further diminished cell viability (Figure 1F). 
Induction of apoptosis by sclareol alone or 
combined with cyclophosphamide
Apoptosis is the major hallmark of cancer 
cell response to anticancer therapies. Hence, 
apoptosis was analyzed in cells treated 
with sclareol, cyclophosphamide, or the 
combination of both compounds. 
As it is shown in Figures 2 A and B, a 
significant increase in both the early and 
late-stage apoptotic cells was observed after 
incubation with 30 μM of sclareol both for 24 
and 48 hours. Co-administration of sclareol and 
cyclophosphamide increased the population of 
cells in both early and late apoptosis compared 
to the control cells (Figures 2 A and B).
 
Figure 2. The results of the flow cytometric analysis of the apoptosis in MCF-7 cells treated with sclareol 
(Scl) (30 µM), cyclophosphamide (Cpm) (8 μM) and their combination, compared with control cells. 
  
Figure 2. The results of the flow cytometric analysis of the apoptosis in MCF-7 cells treated 
with sclareol (Scl) (30 µM), cyclophosphamide (Cpm) (8 μM) and their combination, com-
pared with control cells.
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Induction of apoptotic genes in response to 
sclareol
Sclareol was found to promote apoptosis of 
the breast cancer cells; thus, the expression of 
various apoptosis-related genes such as p53, 
Bcl-2, and Bax, as well as JAK2 and STAT3 
was analyzed to achieve a better understanding 
of how sclareol exerts cytotoxic effects and 
promotes apoptosis. 
First of all MCF-7 breast cancer cells were 
treated with IL-6 which is an established 
promoter of breast cancer progression and its 
inhibition leads to the induction of apoptosis 
(20). Furthermore, the expression levels of 
IL-6 were found to be significantly lower 
in MCF-7 than some other cancer cell lines 
like MDA-MB-231 (21). As it is shown in 
Figure 3A, p53 expression level was 
 
Figure 3. The effect of sclareol (Scl) alone or in combination with either cyclophosphamide (Cpm) or 
cryptotanshinone (Cpt) on IL-6-induced modulation of apoptotic genes expression including p53 (A), 
BAX (B) and Bcl-2 (C). The presented data are mean ± SD of at least three separate experiments. The 
obtained values were compared with the control. Treatment with IL-6 served as positive control. 
  
Figure 3. The effect of sclareol (Scl) alone or in combination with either cyclophosphamide 
(Cpm) or cryptotanshinone (Cpt) on IL-6-induced modulation of apoptotic genes expression 
including p53 (A), BAX (B) and Bcl-2 (C). The presented data are mean ± SD of at least three 
separate experiments. The obtained values were compared with the control. Treatm nt with 
IL-6 served as positive control.
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significantly diminished after the treatment 
of the cells with IL-6. When sclareol was 
added to the cells it could significantly 
abrogate the suppressive effect of IL-6 on p53 
and significantly enhanced p53 expression. 
Similar outcomes were also reported from 
cyclophosphamide. The combination of 
sclareol and cyclophosphamide was even 
more effective in the induction of p53 
expression and repression of the effect of IL-6 
(Figure 3A). 
On the other hand, since JAK/STAT 
pathway is an efficient pathway to suppress 
cancer cell growth and IL-6 exerts its effect 
on breast cancer cells via this pathway, a 
group of cells was treated by a combination 
of IL-6, sclareol, and cryptotanshinone, as the 
STAT3 inhibitor, and the highest increase in 
p53 expression was observed in this group 
indicative of the involvement of JAK/STAT 
pathway in the function of sclareol. 
IL-6 was also able to inhibit the expression 
of BAX, an efficient proapoptotic factor, while 
it induced the expression of Bcl-2 as a potent 
anti-apoptosis factor (Figure 3 B, C). Sclareol 
inhibited the effect of IL-6 and was able to 
significantly induce Bax expression (Figure 3 
B). 
The expression of Bcl2 which was 
increased by IL-6 was significantly 
suppressed when sclareol was added to the 
cells (Figure 3C). Cyclophosphamide also 
changed the effect of IL-6 both on BAX 
and Bcl-2. When cyclophosphamide was 
combined with sclareol, it exerted a significant 
provocative effect and significantly increased 
BAX expression (Figure 3B). Inclusion of 
cryptotanshinone in the cellular treatments, 
enhanced the effect of sclareol on IL-6-
induced modulation of both Bcl-2 and BAX, 
pointing out the role of JAK/STAT pathway in 
this outcome (Figure 3 B, C).  
Enhancement of the JAK/STAT pathway by 
sclareol
As mentioned above, sclareol could inhibit 
the effects of IL-6 on gene expression. Since 
IL-6 functions through the JAK/STAT pathway, 
it was hypothesized that sclareol could modify 
the STAT3 expression and activity. The 
mRNA expression of both STAT3 and JAK2 
was analyzed after treatment with sclareol, 
cyclophosphamide or cryptotanshinone 
together with IL-6. The expression of neither 
JAK2 nor STAT3 was affected by IL-6. The 
addition of sclareol either alone or combined 
with cyclophosphamide or cryptotanshinone 
could not change the gene expression of 
these two signaling proteins showing that 
their regulation by IL-6 and sclareol are not 
achieved at the transcriptional level.
Neither combination was effective on 
the gene expression of STAT3 and JAK2 
(Figure 4A, B), indicating that none of these 
compounds modulate STAT3 and JAK2 at the 
transcriptional level. 
Taking into account the possibility of post-
translational regulation of STAT3 by sclareol, 
docking studies were performed to evaluate 
the interaction between sclareol and STAT3. 
As shown in Figure 5, sclareol was perfectly 
docked into the native hot spot pTyr705 site 
and side pocket of the SH2 domain of STAT3 
with a predicted binding energy of 5.4 kcal/
mol which stabilized the enzyme-inhibitor 
complex. Therefore, sclareol was speculated 
to be a direct inhibitor of STAT3 by interacting 
with the SH2 domain of this protein. 
STAT3 is activated by phosphorylation 
(22). Hence, in the next step, MCF-7 
cells were treated with sclareol and the 
phosphorylation of STAT3 was evaluated 
by Western blotting using specific antibody 
against the phosphorylation form of STAT3 
and compared with other treatments including 
cyclophosphamide as well as IL-6 and 
cryptotanshinone as the inducer and inhibitor 
of STAT3, respectively. 
As shown in Figure 6, treatment 
with IL-6 caused a remarkable increase 
in the phosphorylated form of STAT3 
while cryptotanshinone suppressed the 
phosphorylation of STAT3. Sclareol was 
also able to significantly decrease STAT3 
phosphorylation, an effect that was augmented 
by the addition of cyclophosphamide 
so that co-administration of sclareol and 
cyclophosphamide was even more effective 
in suppression of STAT3 phosphorylation 
compared to each separate treatment (Figure 6). 
Activation of caspases 8 and 9 by sclareol 
As mentioned above, sclareol was able to 
efficiently induce apoptosis and enhance the 
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Figure 4. The effect of sclareol (Scl) in combination with IL-6, cryptotanshinone (Cpt) and 
cyclophosphamide (Cyc) on the gene expression of JAK2 (A) and STAT3 (B) compared to control group 
and the cells treated with IL-6. The presented data are the mean ± SD of at least three separate 
experiments.  
  
Figure 4. The effect of sclareol (Scl) in combination with IL-6, cryptotanshinone (Cpt) and cyclophospha-
mide (Cyc) on the gene expressi n of JAK2 (A) and STAT3 (B) compared to control grou  and the cells 
treated with IL-6. The presented data are the mean ± SD of at least three separate experiments. 
 
Figure 5. Molecular docking model of sclareol (Scl) binding to the STAT3 SH2 domain (PDB: 1BG1) 
generated by autodock vina. The surface of the SH2 domain was colored pale cyan and the key residues 
are shown. Sclareol bound to hot spot pTyr705 site of STAT3 SH2 domain.  
 
  
Figure 5. Molecular docking model of sclareol (Scl) binding to the STAT3 SH2 domain (PDB: 1BG1) generated by autodo-
ck vina. The surface of the SH2 domain was colored pale cyan and the key residues are shown. Sclareol bound to hot spot 
pTyr705 site of STAT3 SH2 domain.
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expression of apoptosis-associated factors. 
Since the main apoptotic pathways are 
executed by caspases including 8, 9 and 3, the 
activities of these caspases were evaluated in 
response to sclareol. Both cyclophosphamide 
and sclareol effectively activated caspases 8 
and 9 (Figure 7). Sclareol activated caspase 9 
more efficiently compared to caspase 8 while 
cyclophosphamide was equally effective on 
both caspases 8 and 9. Cyclophosphamide 
and sclareol had an additive effect on the 
activation of caspases. Since caspase 3 is 
not generally expressed in MCF-7 cells, its 
activity remained unchanged in all treatments 
(Figure 7). 
Discussion
Human breast cancer is a complex 
illness caused by the joint interaction of 
genetic, epigenetic, and environmental factors 
(23). Despite considerable developments 
in the treatment of breast cancer, current 
conventional therapies for this disease still 
have major limitations (24). Thus, novel 
therapeutic strategies are needed to effectively 
modulate various carcinogenic mechanisms. 
Natural compounds such as diterpenes, play 
an important role in chemoprevention and 
in improving the effectiveness of cancer 
treatment by modifying the sensitivity of 
cancer cells to chemotherapeutics (25). 
Sclareol, as a diterpene, is a renowned 
phytochemical that was found to be able 
to potently reduce cell viability and induce 
apoptosis with an IC50 at the micromolar level 
 
Figure 6. The phosphorylation status of STAT3 after treatment of cells with sclar ol (Scl) ither alone or 
combined with cyclophosphamide (Cyc) or cryptotanshinone (Cpt). Untreated cells that received nly the 
solvent (ethanol) were used as negative control and treatment with IL-6 served as the positive control.  
  
Figure 6. The phosphorylation status of STAT3 after treatment 
of cells with sclareol (Scl) either alone or combined with cyclo-
phosphamide (Cyc) or cryptotanshinone (Cpt). Untreated cells 
that received only the solvent (ethanol) were used as negative 
control and treatment with IL-6 served as the positive control. 
 
Figure 7. Activation of caspases 8 and 9 but not 3 by sclareol (Scl) and cyclophosphamide (Cyc). The 
presented data are the mean ± SD of at least three separate experiments. * P<0.05, ** P<0.01, *** 
P<0.001.  
  
Figure 7. Activation of caspases 8 and 9 but not 3 by sclareol (Scl) and cyclophosphamide (Cyc). The presented 
data are the mean ± SD of at least three separate experiments. * P<0.05, ** P<0.01, *** P<0.001. 
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in estrogen receptor (ER)-positive MCF-7 
cells (26). 
Compelling experimental evidence 
from both clinical trials and animal studies 
demonstrated that the JAK2/STAT3 pathway 
plays a pivotal role in the initiation, progression, 
and metastasis of breast cancer (27, 28). The 
present study aimed to find out the molecular 
mechanism underlying sclareol anticancer 
activity, particularly in regards to its effects 
on the JAK2/STAT3 signaling pathway. In 
fact, on the basis of the existing evidence, we 
hypothesized that bioavailable sclareol alone, 
or in combination with cyclophosphamide 
may modulate breast carcinogenesis, primarily 
by inhibiting Stat3 activation. 
Sclareol effects on cell viability and 
apoptosis
In this study, we showed that sclareol 
could effectively diminish cell viability and 
induce apoptosis in breast cancer cells at 
a concentration of 30 μM. In line with our 
findings, antiproliferative and apoptosis-
inducing effects against breast cancer cells have 
been previously described for sclareol (29). It 
has also been shown to reduce cell survival and 
induce cell death in other cancer types such 
as cervical cancer and osteosarcoma (30, 31). 
Sclareol has been reported to sensitize cancer 
cells to various anticancer drugs. For example, 
sclareol enhances the efficacy of doxorubicin, 
etoposide, and cisplatin, against breast cancer 
cells (29) and bortezomib in cervical cancer 
(31). In the current study, we showed for the 
first time that co-administration of sclareol 
and cyclophosphamide exhibited a much more 
potent anti-proliferative effect against breast 
cancer cells and induced apoptosis more 
competently, suggesting that the combination 
of sclareol and cyclophosphamide might be 
considered as a suitable candidate for breast 
cancer treatment.
Apoptosis, the major type of programmed 
cell death, is an active cell suicide process. 
One of the major hallmarks of carcinogenesis 
is a circumvention of apoptosis by cancer 
cells. On the other hand, cancer cell death is 
an essential part of different strategies that 
exist for the elimination of malignant cells. 
Thus, initiation of cell death pathways as well 
as targeting the lesions that suppress cell death 
are exciting remedies for cancer treatment 
(32). 
In this study, we showed for the first 
time that sclareol significantly enhanced the 
expression of major pro-apoptotic proteins 
including p53 and BAX and attenuated the 
expression of Bcl-2 as the chief anti-apoptotic 
factor (Figure 8). 
In addition to serving as the promoter of 
metastasis and a regulator of cell invasion 
(33, 34), Bcl-2 is known to be involved in 
the mediation of chemotherapy resistance in 
some types of cancers (35-38). Accordingly, 
sclareol may have the potential to overcome 
cancer chemoresistance by inhibiting Bcl-2. 
Consistently, the up-regulation of BAX and 
suppression of Bcl-2 by sclareol has been 
previously reported in osteosarcoma cells (14). 
Nevertheless, sclareol has exhibited apoptosis-
promoting properties in p53-null cell lines 
(29) and so it seems that other pathways might 
also be involved in the efficacy of sclareol in 
the induction of cell death. Anyhow, further 
investigation is required to clarify the detailed 
mechanism of these effects by sclareol.
Here we revealed that caspase 8 was 
activated by sclareol which suggests the 
stimulation of the extrinsic pathway of 
apoptosis by this compound. It has been 
established that in case of high levels of 
activated caspase 8, the effector caspases 3, 
6, and 7 are triggered, while in some other 
cell types, activation of caspase 8 leads to 
cytochrome c release from mitochondria 
which forms the apoptosome complex that 
results in stimulation of caspase-9 (39). 
Caspase-9 has been described as the initiator 
of the intrinsic pathway that binds to Apaf-1 
and cytochrome c and then activates caspase-3 
and subsequently leads to apoptosis (40). 
We found out that caspases 8 and 9 were 
activated by sclareol. Thus, based on our 
findings it seems that activation of caspases 
in breast cancer cells in response to sclareol 
follows the latter mechanism and happens 
through the cross-talk between extrinsic and 
intrinsic pathways of apoptosis. Caspase 3 
is not normally expressed in MCF-7 breast 
cancer cells (41), hence its expression was not 
induced in different experimental conditions.  
Meanwhile, the activities of caspase-8 
and -9 were also markedly increased in the 
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MCF-7 cell line co-treated with these two 
compounds comparing to that of either agent 
alone (Figure 7). In addition, we observed that 
the co-treatment more greatly decreased the 
expression of Bcl-2 and increased expressions 
of Bax, compared to either agent treated alone. 
Sclareol effects on the JAK2/STAT3 path-
way
STAT3 is persistently activated in 
numerous cancers and is involved in 
cancer cell proliferation, invasion, and 
migration. Additionally, it tempers epigenetic 
modification, induces epithelial-mesenchymal 
transition and promotes cancer stem cells self-
renewal and differentiation (22). 
Therefore, the present study aimed to 
elucidate the molecular mechanism underlying 
sclareol anticancer activity, particularly in 
regards to its effects on the JAK2/STAT3 
signaling pathway. We showed that sclareol 
could interact with STAT3 and attenuate its 
phosphorylation. As reported in previous 
studies, high concentrations of phosphorylated 
STAT3 (p-STAT3) was reported to be 
associated with high metastatic rate of a 
majority of human cancers (42-44) such as 
lung (45), ovarian (46), colorectal cancers 
(47) and TNBC (48) and their poor survival 
outcomes. In addition, as described previously, 
accumulating evidence suggests that STAT3, 
as a critical multifunctional mediator plays a 
crucial role in the regulation of angiogenesis 
and cell adhesion under both physiological and 
pathological conditions (49-51). However, the 
expression levels of non-phosphorylated JAK2 
and STAT3 themselves were not affected by 
sclareol, suggesting that sclareol may intervene 
 
Figure 8. The pro-apoptotic and anti-apoptotic factors modulated by sclareol in MCF-7 cells. 
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principally at the post-translational phase. 
Additionally, we found that the modulatory 
functions of IL-6 on the expression of 
apoptotic genes were impeded by sclareol. 
Considering the role of IL-6 on the initiation 
of the JAK/STAT pathway, inhibition of the 
IL-6 function by sclareol further verified 
the effect of this compound on hindering 
the STAT3 phosphorylation and activity. 
The addition of cryptotanshinone, a well-
characterized inhibitor of STAT3, to the cells 
treated by sclareol enhanced the inhibitory 
effect of sclareol and confirmed that the effects 
of sclareol on breast cancer cells are mediated 
through JAK/STAT pathway. 
Interestingly it was found that combined 
treatment of sclareol and cyclophosphamide 
attenuated STAT-3 phosphorylation compared 
with groups of sclareol and cyclophosphamide 
treated alone in MCF-7 cell line. 
Taken together, sclareol may be considered 
as a new promising lead for the development 
of active anticancer agents. However, many 
of the properties of sclareol are still unknown. 
Hence, further preclinical and clinical studies 
are needed to figure out sclareol toxicity as 
well as its pharmacokinetic profiles, before 
introducing an officially-marketed medicinal 
product of this compound. 
Conclusion
In conclusion, our findings convincingly 
provided evidence for the efficacy of sclareol 
in attenuation of cell viability and inducing 
apoptosis in MCF-7 breast cancer cell line. 
Furthermore, for the first time, it was found that 
the addition of sclareol to cyclophosphamide 
treatment increased the potency of this anti-
cancer agent via the induction of apoptotic 
cell death as well as inhibition of STAT3 
phosphorylation. The co-treatment-induced 
apoptosis was likely attributable to the 
activation of p53, Bax, caspase 8, and caspase 
9 as well as suppression of Bcl-2. The in-
vitro results also validated the results of the 
molecular docking study. Hence, sclareol 
can be considered as a suitable candidate 
for therapeutic interventions. Further animal 
studies and human clinical trials are required 
to develop sclareol as a treatment option 
against breast cancer. 
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